Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced
non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and
experience significantly varying duration of response and survival rate. Anlotinib is an
efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration
and proliferation of endothelial cells and reduce tumor microvascular density by targeting
VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung cancer
after second-line standard chemotherapy failure, which can significantly extend the survival
of patients and approves as a third-line treatment for advanced NSCLC. Here, we prepared to
evaluate whether the combination of gefitinb and anlotinib can preferably improved survival
of untreated NSCLC with EGFR activating mutation.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.